Want to see TSE:DMED full AI Analyst Report?
Top Page
DiagnaMed Holdings Corp.
(DMED)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.05
▼(-18.33% Downside)
Action:Reiterated
Date:08/29/26
The score is primarily held down by weak financial performance (no revenue, widening losses, ongoing cash burn, and negative equity despite no debt). Technical indicators provide only modest support (near-term strength vs. key short/mid-term averages, but still below the 200-day), while valuation is constrained by negative earnings and no dividend yield.
Positive Factors
No Reported Debt
The absence of reported debt reduces direct leverage and interest-burden risk, giving the company a simpler capital structure than a highly indebted counterpart. This provides some financial flexibility if management can secure funding and advance its health-technology initiatives.
Negative Factors
No Reported Revenue
The absence of reported revenue indicates that the business has not yet demonstrated commercial traction or an internally funded operating model. Without sales, progress depends on converting its health-technology and medical-innovation focus into sustainable revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
No Reported Debt
The absence of reported debt reduces direct leverage and interest-burden risk, giving the company a simpler capital structure than a highly indebted counterpart. This provides some financial flexibility if management can secure funding and advance its health-technology initiatives.
Read all positive factors
DiagnaMed Holdings Corp. (DMED) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$6.58M
Dividend YieldN/A
Average Volume (3M)252.69K
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue GrowthN/A
EPS Growth-28.35%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding131,559,310
10 Day Avg. Volume353,084
30 Day Avg. Volume252,691
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-21.78
Price to Sales (P/S)0.00
P/FCF Ratio-29.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DiagnaMed Holdings Corp. Business Overview & Revenue Model
Company Description
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and pr...
DiagnaMed Holdings Corp. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -24.71K | -16.05K |
| EBITDA | -1.84M | -1.40M | -501.00K | -100.00K | -1.13M | -1.95M |
| Net Income | -1.85M | -1.40M | -501.00K | -1.28M | -1.13M | -1.95M |
Balance Sheet | ||||||
| Total Assets | 330.82K | 216.36K | 201.75K | 662.27K | 1.62M | 2.39M |
| Cash, Cash Equivalents and Short-Term Investments | 293.76K | 183.83K | 162.15K | 606.96K | 1.57M | 2.36M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 508.82K | 666.47K | 466.91K | 426.38K | 369.51K | 150.24K |
| Stockholders Equity | -178.00K | -450.11K | -265.17K | 235.89K | 1.25M | 2.24M |
Cash Flow | ||||||
| Free Cash Flow | -582.73K | -336.07K | -444.82K | -1.07M | -787.58K | -565.60K |
| Operating Cash Flow | -582.73K | -336.07K | -444.82K | -1.07M | -787.58K | -565.60K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.07K |
| Financing Cash Flow | 615.02K | 357.75K | 0.00 | 104.25K | 0.00 | 2.89M |
DiagnaMed Holdings Corp. Technical Analysis
Negative
0.06
Price Trends
0.05
Negative
0.06
Negative
0.07
Negative
Market Momentum
<0.01
Positive
43.67
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DMED, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 43.67 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DMED.
DiagnaMed Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$57.20M | -11.50 | 9999.00% | ― | -36.92% | 13.03% | |
45 Neutral | C$6.58M | -3.23 | 739.84% | ― | ― | -28.35% | |
45 Neutral | C$12.90M | -1.99 | 64.52% | ― | 7.63% | -106.03% | |
44 Neutral | C$56.20M | -2.16 | -444.52% | ― | 415.06% | -54.80% | |
42 Neutral | C$11.23M | -3.24 | 6239.15% | ― | ― | 68.00% | |
41 Neutral | C$4.21M | -1.45 | 184.91% | ― | ― | 43.30% |
* Healthcare Sector Average
TSE:DMED
DiagnaMed Holdings Corp.
0.05
-0.04
-41.18%
TSE:ADK
Diagnos
0.48
0.21
82.69%
TSE:AIDR
Rocket Doctor AI
0.58
-0.11
-15.94%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.45
-0.05
-11.00%
TSE:UDOC
UniDoc Health Corp
0.13
-0.07
-35.00%
TSE:NARA
PanGenomic Health, Inc. Class A
0.30
-2.04
-87.18%
DiagnaMed Holdings Corp. Corporate Events
Business Operations and StrategyExecutive/Board Changes
DiagnaMed reshapes board as it sharpens focus on natural clean hydrogen
Positive
Aug 24, 2026
DiagnaMed Holdings Corp. has appointed energy-law specialist Charles Turmel to its board, adding governance, regulatory and corporate finance expertise as it pivots more decisively into natural clean hydrogen. His appointment coincides with the re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.